Pediatric Neurogenic Bladder Cases Are Not Fully Evaluated

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 3, 2023.

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 3, 2023 -- Pediatric neurogenic bladder (NGB) cases are not fully evaluated in routine clinical practice, according to a study published online Oct. 16 in Advances in Therapy.

Naoko Izumi, from Pfizer Japan in Tokyo, and colleagues conducted a retrospective cohort study involving patients aged 17 years and younger with NGB to examine the current status of NGB management over a 24-month follow-up. Data were included for 883 eligible children, including 39.3 percent with spina bifida.

The researchers found that renal urinary tract ultrasound and urinalysis were performed at least once in >35 and >45 percent of patients over 12-/24-month post-index periods, respectively, while substantially fewer patients underwent specific tests (urodynamics, cystourethrography, scintigraphy; <11/<13 percent). Overactive bladder medications were used by 21.5 percent of patients over 24 months, and 10.8 percent of patients underwent clean intermittent catheterization (CIC) alone or with medications; 1.2 percent underwent surgery. The most common incident complications were lower urinary tract infection (UTI), urinary incontinence, and hydronephrosis (23.2, 9.7, and 7.0 percent, respectively). In an analysis of risk factors for UTI, significantly higher odds ratios were seen for CIC, presence of spina bifida, and constipation (5.70, 2.86, and 2.07, respectively). There was inadequate performance of urodynamic assessments overall.

"Our present study shows that NGB cases are not fully evaluated in routine clinical practice, both for diagnostic and follow-up purposes, despite clear directions provided by the guidelines," the authors write. "This may hamper the ongoing management of these patients and adversely affect the outcomes."

The study was funded by Pfizer Japan.

Abstract/Full Text

Source: HealthDay

Posted : 2023-11-04 02:36

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords